ALX Oncology doubles down on lead CD47 inhibitor after asset fails 2 midstage cancer trials
Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping further attempts in the indication as a result.
Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping further attempts in the indication as a result.
